Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
life sciences
national blog main
4
×
boston top stories
clinical trials
boston
drugs
eli lilly
fda
indiana blog main
indiana top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
accelerated approval
acute hepatic porphyria
alnylam pharmaceuticals
alprazolam
amgen
aminolevulinic acid
biontech
biotech
blueprint medicines
boehringer ingelheim
boulder/denver blog main
boulder/denver top stories
cancer
cgrp inhibitors
chronic migraine
colucid pharmaceuticals
companion diagnostic
curevac
deals
detroit blog main
detroit top stories
dna sequencing
drug enforcement administration
What
new
4
×
second
4
×
drug
cancer
fda
medicine
oks
pharmaceutical
rna
time
acute
addresses
alnylam
approval
approved
bets
bio
causes
cleared
comes
companies
condition
cut
data
date
deal
decades
deeper
dna
effective
eli
enticed
evidence
far
fingerprint
friday
genetic
giant
giving
going
Language
unset
Current search:
second
×
new
×
" national blog main "
×
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines
